Capsaicin applied to human skin provokes a response known as neurogenic inflammation. Neuropeptides (substance P, CGRP), released from afferent C-fiber terminals and histamine, secondarily released from mast cells, are supposed to participate in this reaction. We investigated the contribution of arachidonic acid and metabolic products to neurogenic inflammation, using a potent topically applied glucocorticoid and the corresponding vehicle. Arachidonic acid is liberated from membrane phospholipids by phospholipase A2, an enzyme that can be blocked by glucocorticoids. In 12 healthy volunteers, neurogenic inflammation was induced by capsaicin 1% on both upper forearms after 16h of topical pretreatment with either prednicarbate or vehicle. Neurogenic inflammation was assessed by laser Doppler flowmetry and by planimetry of flare sizes. Prednicarbate significantly reduced the laser Doppler flow values inside the flare responses, as well as the flare sizes themselves. These results show that to some extent glucocorticoids reduce capsaicin-induced neurogenic inflammation.
Introduction
Capsaicin application to the skin causes vasodilatation extending beyond the area of application. This response is called neurogenic inflammation. It is supposed that the visible redness (flare) is due to axon reflex vasodilatation via primary afferent neurones (C-fibers), having an efferent function, i.e. liberating neuropeptides (e.g. substance P, CGRP) from their terminals [13. Besides these neuropeptides, other endogenous vasoactive agents have been suspected to participate in neurogenic inflammation. The present study was undertaken in order to assess the eventual contribution of arachidonic acid to capsaicin-induced neurogenic inflammation. Arachidonic acid is liberated from membrane phos-* Author for correspondence. pholipids by phospholipase A 2. This process is inhibited by glucocorticoids in a complex manner [2] . This report is addressed to the following questions: 1. What is the effect of topically applied glucocorticoid on capsaicin-induced neurogenic inflammation in human forearm skin? 2. Does the inhibition of arachidonic acid liberation from membrane phospholipids influence capsaicin-induced neurogenic inflammation?
Materials and methods

Pretreatment with prednicarbate cream and vehicle cream
After obtaining informed consent, 12 healthy volunteers (aged 22 31yr) participated in this study, which was approved by the local ethics committee. Using a randomized schedule for the choice between left and right side, 3 g prednicarbate containing cream (Dermatop| Casella Riedel) and 3 g vehicle cream (Dermatop| Basiscreme, Casella Riedel), respectively, .were applied to square areas (6 • 6 cm 2) on both the upper forearms. The cream layers were covered with occlusive dressings overnight for 16h. Two hours after removal of the cream bandages, the skin was pretreated with DMSO 10% (Merck) for 1 h to improve capsaicin absorption.
Induction and assessment of capsaicin-induced neuroqenic inflammation
Neurogenic inflammation was induced by 1001A capsaicin 1% (Serva) soaked up in a plaster (Hansaplast), 13 • 18mm 2, applied to the skin for 25 min. The extent of the skin reaction to capsaicin was assessed by measuring the superficial cutaneous blood flow (SCBF) with laser Doppler flowmetry (LDF) (PeriFlux PF3, PERIMED, Sweden), and by planimetry of flare sizes, i.e. the local visible redAgents Actions, Special Conference Issue (1993) ness. A special holder for the LDF probe was used defining the positions of 12 measuring points on the skin: 4 measuring points inside the application area reflecting the direct action of the substance capsaicin plus an eventual neurogenic inflammation (inside SCBF); 8 peripheral measuring points demonstrating the effects induced by neurogenic inflammation only (outside SCBF). Inside SCBF and outside SCBF were calculated as the means of the respective 4 central and 8 peripheral LDF values. In both series SCBF at rest were subtracted from the test result. All results are expressed as mean _+ SD. The "Wilcoxon signed rank test" was used for statistical analyses (significance level: p < 0.05). 
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Discussion
The small but statistically insignificant difference between SCBF at rest on the corticoid pretreated side versus the vehicle side is in accordance with Bisgaard et al. [3] . It has been shown that glucocorticoids are capable of reducing the endogenous release of arachidonic acid by inhibition of phospholipase A 2 [4] . Glucocorticoids are also suggested to inhibit the synthesis of prostaglandins by inhibition of prostaglandin synthase enzyme expression and by coupling lipocortin to membrane phospholipids, in this way reducing the liberation of arachidonic acid [2] . In this study, prednicarbate diminished neurogenic inflammation (flare size as well as SCBF, both significantly by 18%). In investigations described elsewhere in these proceedings, we have shown that treatment with acetylsalicylic acid or indomethacin, i.e. a presumed blockade of prostaglandin synthetase, had no effect on capsaicin-induced neurogenic inflammation. The effectiveness ofa glucocorticoid and the ineffectiveness of ASA/indomethacin indicates that arachidonic acid or related metabolic products other than those derived from cyclooxygenase pathway may be involved in the development of neurogenic inflammation. Another mode of action of the glucocorticoids could also explain our results, namely their inhibition of the expression of Ca 2+-independent NO synthase, assuming that the potent endogenous vasodilator NO does participate in neurogenic inflammation. This line of reasoning derives from the finding that, in contrast to constitutive Ca 2 +-dependent NO synthase, the expression of Ca2+-independent NO synthase is inhibited by glucocorticoids [5] .
